Skip to main content
. 2018 Oct 10;10:4421–4438. doi: 10.2147/CMAR.S176088

Table 1.

LINE-1 ORF-1p expression and clinical outcome of sorafenib treatment

LINE-1 ORF-1p mRNA expression P-value
High (n=24) Low (n=28)

TTP 8.0 11.0 0.0002
6.8–10.6 months 9.1–12.0 months
OS 10.0 14.0 0.0381
6.1–13.8 months 11.4–16.3 months
Overall response rate (PR) 1 (4.17%) 3 (10.71%)
Disease control rate (PR+SD) 4 (16.67%) 9 (32.14%)

Abbreviations: CR, complete remission; OS, overall survival; PR, partial remission; SD, stable disease; TTP, time to progression.